Navigation Links
District Court Decision Received In Remodulin Patent Case
Date:8/29/2014

SILVER SPRING, Md., Aug. 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. District Court for the District of New Jersey has ruled in its favor in the company's case against Sandoz, Inc. regarding United Therapeutics' Remodulin® product.  In his opinion, Judge Peter Sheridan ruled that U.S. Patent No. 6,765,117 is both valid and enforceable against Sandoz, Inc., and enjoined Sandoz from marketing its generic product until the expiration of that patent in October 2017.  Judge Sheridan also ruled that U.S. Patent No. 7,999,007 expiring in 2029 is valid, but would not be infringed by Sandoz' generic product.  Sandoz filed an Abbreviated New Drug Application in December 2011 seeking to market a generic version of Remodulin, and challenged patents covering Remodulin as part of that application.  United Therapeutics filed the lawsuit that is the subject of this ruling shortly thereafter.

"We are pleased with the Court's ruling today confirming the validity and enforceability of the '117 patent," said United Therapeutics' CEO, Martine Rothblatt. "We have always emphasized our investment in scientific advances and the resulting intellectual property that allows us to bring our products to patients, and this decision is a validation of that emphasis."

United Therapeutics is analyzing the Court's opinion and assessing its next steps with respect to the '007 patent, which may include an appeal of the ruling to the U.S. Court of Appeals for the Federal Circuit.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, among others, statements regarding United Therapeutics' patents, including next steps with respect to the '007 patent.  These forward-looking statements are subject to certain risks and uncertainties and are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K, which could cause actual results to differ materially from anticipated results. We are providing this information as of August 29, 2014, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.  [uthr-g]

Remodulin is a registered trademark of United Therapeutics Corporation.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
2. Medical Marijuana Inc. in a Strong Market Position with Amendment 64 in Colorado, Initiative 502 in Washington and the Pending Ninth District Decision Regarding the Schedule 1 Status of Medical Marijuana on a Federal Level
3. Comprehensive Care Corporation Announces Pharmacy Savings Management Agreement With Utica City School District
4. Intersurgical, ERDRICH Umformtechnik, Bridgestone Collaborates with Changzhou National Hi-Tech District
5. Intersurgical, ERDRICH Umformtechnik und Bridgestone gehen Kooperation mit dem Changzhou National Hi-Tech District ein
6. Depomed Announces District Court Order in ANDA Litigation
7. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
8. Lilly Statement on Affordable Care Act Ruling by Supreme Court
9. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
10. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
11. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 2017 Theravance Biopharma, Inc. (NASDAQ: ... today announced the presentation of positive clinical data ... pan-Janus kinase (JAK) inhibitor designed to be intestinally ... the European Crohn,s and Colitis Organization (ECCO). In ... from its completed Phase 1 study of single-ascending ...
(Date:2/17/2017)... , Feb. 17, 2017  In partnership with ... Friends for Good Health , The Jack Brewer ... filled with millions of dollars, worth of medicine to ... Haiti . IHI is a non-profit dedicated to treating ... is extremely active in Haiti ...
(Date:2/17/2017)...  Noble Capital Markets announced today that it has ... EPIX ). The report was issued by Noble,s ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical ... Its lead compound EPI-506, is a small molecule oral ... androgen receptor, thereby has potential to overcome some of ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... sustainable systems change designed to further positively impact the health and wellness of ... has long considered it our duty to seriously consider releasing our assets beyond ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering ... Francis' goals for each and every seminar, session and class she offers. ... five different brainwave tools which help energize creativity, focus mental functions, enhance athletic ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... 2017 season , Trinity Health and the U.S. Soccer Foundation announced today that ... in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... planning assistance to families and business owners in the greater Fort Lauderdale metropolitan ... organization. , For more than 30 years, LifeNet 4 Families has provided ...
Breaking Medicine News(10 mins):